The Concept of CMREvaluating CMRManaging CMRDocumentation Center
Print this pageDecrease text sizeIncrease text size

The Concept of CMR

Epidemiology

Epidemiological studies published over the last 50 years have shed light on the many factors that increase cardiovascular disease (CVD) risk. It is now widely accepted that an altered lipid profile including high cholesterol, LDL cholesterol (bad cholesterol), and triglyceride concentrations as well as low HDL cholesterol (good cholesterol), high blood pressure, smoking, and a sedentary lifestyle all increase one’s risk of CVD. Also considered a major CVD risk factor, type 2 diabetes is defined by high blood glucose levels. Though obesity is an acknowledged health hazard and a risk factor for CVD and type 2 diabetes, physicians have long been puzzled by the remarkable heterogeneity seen in clinical practice among individuals with similar excess body weight. Some obese patients have no clinical signs of CVD or type 2 diabetes, whereas other patients—who may be only slightly or moderately overweight—have a metabolic profile that predisposes them to CVD and/or type 2 diabetes. Studies have shown that the risk of CVD and type 2 diabetes does not depend on excess body weight per se, but rather on the location of this excess weight. Excess abdominal fat plays the greatest role in this regard.  

Document Center


A Simplified View of Victor Dzau´s Cardiovascular Continuum by Luis Miguel Ruilope, MD

A Simplified View of Victor Dzau´s Cardiovascular Continuum by Luis Miguel Ruilope, MD

More

Which factors/markers do you think will emerge as key predictors of global CMR beyond the Framingham risk score?

Which factors/markers do you think will emerge as key predictors of global CMR beyond the Framingham risk score?

More

Post-AHA 2007: Lifestyle intervention

Post-AHA 2007: Lifestyle intervention

More

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 2008;197:355-62

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 2008;197:355-62

More

Evidence for a greater relative accumulation of intra-abdominal adipose tissue (AT) in Japanese than Caucasian Americans

Evidence for a greater relative accumulation of intra-abdominal adipose tissue (AT) in Japanese than Caucasian Americans

More